Multicentric Type 3 Gastric Neuroendocrine Tumors

A 50-year-old woman with incidentally detected multiple gastric polyps and biopsy-proven neuroendocrine tumor (NET) was referred to our hospital. More than 10 polypoid lesions (less than 15 mm) with normal gastric mucosa were detected from the gastric body to the fundus. The serum level of gastrin was within the normal limits. There was no evidence of atrophic changes on endoscopy and serologic marker as pepsinogen I/II ratio. Computed tomography of the abdomen and pelvis revealed no evidence of metastatic lesions. She refused surgery, and we performed endoscopic polypectomy for almost all the gastric polyps that were greater than 5 mm. Although the histological examination revealed that all the removed polys were diagnosed as NET G1, three of them extended to the lateral or vertical resection margins, while two exhibited lymphovascular invasion. A follow-up upper endoscopy that was performed 6 months after the diagnosis showed multiple remnant gastric polyps that were suggestive of remnant gastric NET.

[1]  J. Ramage,et al.  Review article: the investigation and management of rectal neuroendocrine tumours , 2014, Alimentary pharmacology & therapeutics.

[2]  J. Ramage,et al.  Review article: the investigation and management of gastric neuroendocrine tumours , 2014, Alimentary pharmacology & therapeutics.

[3]  K. Choi,et al.  Long-term follow up of endoscopic resection for type 3 gastric NET. , 2013, World journal of gastroenterology.

[4]  G. Kaltsas,et al.  Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. , 2013, European journal of endocrinology.

[5]  H. Sasano,et al.  ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms , 2011, Neuroendocrinology.

[6]  J. Fléjou [WHO Classification of digestive tumors: the fourth edition]. , 2011, Annales de pathologie.

[7]  E. Pilozzi,et al.  Type I Gastric Carcinoids: A Prospective Study on Endoscopic Management and Recurrence Rate , 2011, Neuroendocrinology.

[8]  I. Modlin,et al.  The epidemiology of gastroenteropancreatic neuroendocrine tumors. , 2011, Endocrinology and metabolism clinics of North America.

[9]  O. Louthan [Gastric neuroendocrine tumors]. , 2009, Vnitrni lekarstvi.

[10]  Manal M. Hassan,et al.  Risk factors associated with neuroendocrine tumors: A U.S.‐based case–control study , 2008, International journal of cancer.

[11]  J. Kountouras,et al.  Diffuse gastric carcinoid polyposis in multiple endocrine neoplasia 1 syndrome without hypergastrinemia. , 2007, Gastrointestinal endoscopy.

[12]  I. Modlin,et al.  A 50-Year Analysis of 562 Gastric Carcinoids: Small Tumor or Larger Problem? , 2004, American Journal of Gastroenterology.

[13]  I. Modlin,et al.  A 5‐decade analysis of 13,715 carcinoid tumors , 2003, Cancer.

[14]  H. Shibusawa,et al.  A case of multiple gastric carcinoids associated with multiple endocrine neoplasia type 1 without hypergastrinemia. , 1999, Gastrointestinal Endoscopy.

[15]  M. Brandi,et al.  Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I. , 1997, The American journal of surgical pathology.

[16]  M. Stolte,et al.  Gastric Carcinoids and Neuroendocrine Carcinomas: Pathogenesis, Pathology, and Behavior , 1996, World Journal of Surgery.

[17]  P. Spinelli,et al.  Endoscopic treatment of gastric carcinoids. , 1994, Minerva Chirurgica.

[18]  O. Luinetti,et al.  Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. , 1993, Gastroenterology.

[19]  K. Hizawa,et al.  A case of multicentric gastric carcinoids without hypergastrinemia. , 2003, Endoscopy.

[20]  C. Bordi,et al.  Hypergastrinemia and gastric enterochromaffin-like cells. , 1995, The American journal of surgical pathology.

[21]  H. al Sayer,et al.  Gastric carcinoids. , 1988, Journal of the Royal College of Surgeons of Edinburgh.